Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.

Today Argenx, an Aescap Life Sciences company, has announced positive results for its final clinical trial in patients diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy).

Several of the Aescap portfolio companies in both the Aescap Life Sciences and Aescap Genetics fund have an internal team with hundreds of AI experts. Is this just a hype or is there a real added value? And what are they aiming for?

UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.

We are reporting to you from the JPMorgan conference in San Francisco where Ipsen and our portfolio company Albireo announced that Ipsen has made an offer to acquire Albireo

Portfolio company Zai Lab and its partner Novocure announced that the phase 3 study investigating their new therapy for late-stage lung cancer patients resulted in improved overall survival

Biotech companies are rapidly developing new technologies to treat previously incurable diseases.

From treatment of symptoms to cure. The number of genetic medicines that are so advanced in R&D that they are tested on humans has been increasing by an average of 27% per year since 2016.

Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.

Solid performance across portfolio. Due to a strong net performance of +13,2% since we published our NAV of mid June, the net performance of the fund for June ended at +8,8%.